What question did this study set out to answer?

The aim is to determine the safety and efficacy of amyloid-targeting monoclonal antibodies in treating mild cognitive impairment and Alzheimer's disease.

May 16, 2026Open Access

Treating dementia with brain amyloid medications

MKMichael R. KolberUniversity of Alberta CKChristina KorownykUniversity of Alberta

Key Points

The aim is to determine the safety and efficacy of amyloid-targeting monoclonal antibodies in treating mild cognitive impairment and Alzheimer's disease.
Conducted randomized controlled trials of monoclonal antibodies in dementia and mild cognitive impairment.
Evaluated cognitive scores as primary outcome measure.
No clinically meaningful improvements observed in cognitive scores among patients treated with monoclonal antibodies.

Abstract

Are amyloid-targeting monoclonal antibodies safe and effective for mild cognitive impairment (MCI) or Alzheimer disease? Randomized controlled trials (RCTs) of monoclonal antibodies for patients with dementia or MCI found no clinically meaningful improvements in cognitive scores. These medications

AIに質問

Bookmark

View Full Paper

Cite This Study

Kolber et al. (Fri,) studied this question.

synapsesocial.com/papers/6a080969a487c87a6a40b462 https://doi.org/https://doi.org/10.46747/cfp.7205330

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AIに質問

Bookmark

View Full Paper